Popular drug does not alleviate mild COVID symptoms: Study
SECTIONS
Last Updated: Mar 05, 2021, 10:22 AM IST
Share
Synopsis
Some studies have indicated that Ivermectin can prevent several different viruses from replicating in cells. And last year, researchers in Australia found that high doses of ivermectin suppressed SARS-CoV-2, the virus that causes COVID-19, in cell cultures.
AFP
Such findings had spurred use of the drug against COVID-19, especially in Latin America.
Ivermectin, a controversial anti-parasitic drug that has been touted as a potential COVID-19 treatment, does not speed recovery in people with mild cases of the disease, according to a randomized controlled trial published Thursday in the journal JAMA.
Australia
Colombia
United-states
Barcelona
Comunidad-autonoma-de-cataluna
Spain
America
Carlos-chaccour
Regina-rabinovich
National-institutes-of-health
Barcelona-institute-for-global-health
Pediatric-infectious-diseases
Credit: ISGlobal/Clínica Universidad de Navarra.
A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission. The study, which is part of the SAINT project and has been led by the University of Navarra Clinic and the Barcelona Institute for Global Health (ISGlobal), an institution supported by the la Caixa Foundation, warrants further exploration in larger clinical trials. The findings of the pilot study have been published in
EClinicalMedicine, a clinical journal published by The Lancet.
We already have two approved COVID-19 vaccines in the European Union, but immunising enough people worldwide to stop viral spread will require at least two years. Meanwhile, finding drugs that can treat or prevent infections remains a priority. Many efforts are focusing on developing treatments for COVID-19, but few are addressing how to reduce viral transm
Bangladesh
United-states
Argentina
Barcelona
Comunidad-autonoma-de-cataluna
Spain
American
Carlos-chaccour
University-of-navarra-clinic
University-of-barcelona
Global-development
Pompeu-fabra-university